Axicabtagene Ciloleucel and Tisagenlecleucel CAR T-cell therapies for the treatment of relapsed or refractory follicular lymphoma
Connect2Clinic
An end-to-end Practice Management Platform that makes your In-Clinic & Online practice seamless!
The primary objective of this study was to conduct a comparative analysis of Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) concerning their efficacy, safety, and cost-effectiveness in the treatment of relapsed or refractory follicular lymphoma (rrFL) after at least two prior lines of treatment. Notably, Axi-cel exhibited a significant association with higher incidences of cytokine release syndrome (CRS), neurologic events, and the occurrence of grade 3-4 adverse events (AEs) when compared to Tisa-cel. In contrast, Tisa-cel demonstrated a more favorable safety profile, fewer serious AEs, a lower mortality rate, and a reduced overall cost in comparison to Axi-cel. These findings emphasize the potential advantages of Tisagenlecleucel in the treatment of rrFL.